Raft-Forming Agents: Antireflux Formulations

REFERENCES

• Beekman S. M. Preparation and properties of new gastric antacids. J. Am. Pharm. Assoc. Sci. Ed. 1960; 49: 191–200
   Google Scholar
• Brooks W. J. Rafting antacid formulation. US Patent 5,360,793, 1994, November 1, 1994
   Google Scholar
• Chavkin L. Dry, water-foamable pharmaceutical compositions. US Patent 4,613,497, 1986, September 23, 1986
   Google Scholar
• Davies N. M., Farr S. J., Kellaway I. W., Taylor G., Thomas M. A comparison of the gastric retention of alginate containing tablet formulations with and without the inclusion of excipient calcium ions. Int. J. Pharm. 1994; 105: 97–101
   Web of Science ®Google Scholar
• Dettmar P. W., Dickson A. P., Hampson C. F., Jolliffe G. I. Compositions for treatment of disorders of the oesophagus. US Patent 6,610,667, 2003, August 26, 2003
   Google Scholar
• Dettmar P. W., Little S. L., Baxter T. The Effect of omeprazole pre-treatment on rafts formed by reflux suppressant tablets containing alginate. J. Int. Med. Res. 2005; 33: 301–308
   PubMed Web of Science ®Google Scholar
• Eccleston G., Paterson R. Gastric raft composition. US Patent Application 20050063980, 2005, March 24 2005
   Google Scholar
• Field F. P. Composition and method for treatment of gastrointestinal distress. US Patent 5,681,827, 1997, October 28, 1997
   Google Scholar
• Foldager J., Toftkjor H., Kjornos K. Antacid composition. US Patent 5,068,109, 1991, November 26, 1991
   Google Scholar
• Fuchs C. Antacids, their function, formulation, and evaluation. Drug Cosmetic Ind. 1949; 64: 692–773
   PubMedGoogle Scholar
• Gayst S., Maguire M. J. Pharmaceutical formulation of guar gum. US Patent 4,315,918, 1982, February 16, 1982
   Google Scholar
• Geoffrey C. W., Henry I. J. Gastroesophageal reflux disease. Am. J. Pharm. Edu. 2003; 66: 148–152
   Web of Science ®Google Scholar
• Goodall J. S., Orwin J. M., Imrie M. J. A combined pH and X-ray study of liquid alginate/antacid formulation using a novel X-ray contrast medium. Acta Therapeutica 1977; 3: 141–153
   Google Scholar
• Grant G. T, Morris E. R, Rees D. A, Smith P. J. C., Thom D. Biological interactions between polysaccharides and divalent cations: the egg box model. FEBS Lett. 1973; 32: 195–198
   Web of Science ®Google Scholar
• Gregory S., Kelly N. D. Hydrochloric Acid: Physiological Functions and Clinical Implications. Alt. Med. Rev. 1997; 2(2)116–127
   Google Scholar
• Hampson F. C., Farndale A., Strugala V., Sykes J., Dettmar P. W. Alginate rafts and their characterization. Int. J. Pharm. 2005; 294: 137–147
   PubMed Web of Science ®Google Scholar
• Havelund T., Aalykke C. The efficacy of a pectin-based raft-forming anti-reflux agent in endoscopy-negative reflux disease. Scand. J. Gastroenterol. 1997a; 32: 773–777
   PubMed Web of Science ®Google Scholar
• Havelund T., Aalykke C., Rasmussen L. Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease. Eur. J. Gastroenterol. Hepatol. 1997b; 9(5)509–514
   PubMed Web of Science ®Google Scholar
• Hill E. A., Wade G. Investigation into the use of viscometry for in vitro characterization of the raft forming properties of tablets containing alginic acid and antacid components. Drug Dev. Ind. Pharm. 1993; 19(5)1931–1937
   Google Scholar
• Holbert J. M., Noble N., Grote I. W. Study of antacid buffers, time factor in neutralization of gastric acidity. J. Am. Pharm. Assoc. Sci. Ed. 1947; 36: 149–151
   Google Scholar
• Hoogerwerf W. A., Pasricha P. J. Goodman and Gilman's, The Pharmacological Basis of Therapeutics10th edition, International. 1005–1017
   Google Scholar
• Irvine E. J. Quality of life assessment in gastro-oesophageal reflux disease. Gut 2004; 53(4)35–39
   Google Scholar
• Jenkins J. R. F., Hardy J. G., Wilson C. G. Monitoring antacid preparations in the stomach using gamma scintigraphy. Int. J. Pharm. 1983; 14: 143–148
   Google Scholar
• Johnson F. A., Craig D. Q. M., Mercer A. D., Chauhan S. The effects of alginate molecular structure and formulation variables on the physical characteristics of alginate raft systems. Int. J. Pharm. 1997; 159: 35–42
   Web of Science ®Google Scholar
• Johnson L. F., DeMeester T. R. Evaluation of elevation of the head of the bed, bethanechol, and antacid form tablets on gastroesophageal reflux. Dig. Dis. Sci. 1981; 26(8)673–680
   PubMed Web of Science ®Google Scholar
• Jolliffe I. G., Hampson F. C., Campbell R., Dettmar P. W. In vitro reflux resistance in alginate rafts. Gut 2001; 48: A26
   Web of Science ®Google Scholar
• Jung A. D. Gastroesophageal reflux in infants and children. Am. Fam. Physician. 2001; 64(11)1853–1860
   PubMed Web of Science ®Google Scholar
• Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease – an analysis based on the ProGERD initiative. Aliment. Pharmacol. Ther. 2003; 18: 767–776
   PubMed Web of Science ®Google Scholar
• Lu C. L., Lang H. C., Chang F. Y., Chan T. J., Chan C. Y., Luo J. C., Lee S. D. Social and medical impact, sleep quality and the pharmaceutical costs of heartburn in Taiwan. Aliment. Pharmacol. Ther. 2005; 22: 739–747
   PubMed Web of Science ®Google Scholar
• Malmud L. S., Charles N. D., Littlefield J. The mode of action of alginic acid compound in the reduction of gastroesophageal reflux. J. Nuc. Med. 1979; 20(10)1023–1028
   PubMed Web of Science ®Google Scholar
• Mandel K. G., Daggy B. P., Jacoby H. I. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment. Pharmacol. Ther. 2000; 1: 669–690
   Google Scholar
• Mandlekar S. V., Marathe S. S., Devarajan P. V. A novel raft-forming antacid suspension using a natural dietary fibre. Int. J. Pharm. 1997; 148: 117–121
   Google Scholar
• May H. A., Wilson C. G., Hardy J. G. Monitoring radiolabeled antacid preparations in the stomach. Int. J. Pharm. 1984; 19: 169–176
   Web of Science ®Google Scholar
• Moss H. A., Washington N., Greaves J. L., Wilson C. L. Anti-reflux agents, stratification or floatation?. Eur. J. Gastroenterol. Hepatol. 1990; 2: 45–51
   Google Scholar
• Nebel O. T., Fornes M. F., Castell D. O. Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am. J. Dig. Dis. 1976; 21: 953–956
   PubMedGoogle Scholar
• Richter J. E. Severe reflux esophagitis. Gastrointest. Endosc. Clin. North Am. 1994; 4: 677–698
   PubMedGoogle Scholar
• Rossett N. E., Rice M. L. An in vitro evaluation of the efficacy of more frequently used antacids with particular attention to tablets. Gastroenterology 1954; 26(3)490–495
   Web of Science ®Google Scholar
• Sandler R. S., Everhart J. E., Donowitz M., et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500–1511
   PubMed Web of Science ®Google Scholar
• Scott M., Gelhot A. R. Gastroesophageal Reflux Disease: Diagnosis and Management. Am. Fam. Physician. 1999; 59(5)1161
   PubMed Web of Science ®Google Scholar
• Smyth R. D., Herczeg T., Wheatley T. A., House W., Reavey-Cantwell N. H. Correlation of in vitro and in vivo methodology for evaluation of antacids. J. Pharm. Sci. 1976; 65: 1045–1047
   PubMed Web of Science ®Google Scholar
• US Patent 2,774,710 issued to Thomson, K, December 1956 (crossreference obtained from US Patent 5,360,793).
   Google Scholar
• US Patent 5,112,813 issued to Rhone, R., P, May 12, 1992 (crossreference obtained from US Patent 5,360,793).
   Google Scholar
• Vatier J., Celice-Pinguad C., Farinotti. A computerized artificial stomach model to assess sodium alginate-induced pH gradient. Int. J. Pharm. 1998; 163: 225–229
   Google Scholar
• Washington N., Washington C., Wilson C. G., Davis S. S. Effect of aluminium hydroxide on ‘raft forming’ antacids. J. Pharm. Pharmacol. 1985a; 37: 13P
   PubMed Web of Science ®Google Scholar
• Washington N., Washington C., Wilson C. G., Davis S. S. The effect of inclusion of aluminum hydroxide in alginate-containing raft-forming antacids. Int. J. Pharm. 1986; 28: 139–143
   Web of Science ®Google Scholar
• Washington N., Wilson C. G., Davis S. S. Evaluation of ‘raft-forming’ antacid neutralizing capacity : in vitro and in vivo correlations. Int. J. Pharm. 1985b; 27: 279–286
   Google Scholar
• Washington N., Wilson C. G., Greaves L., Danneskiold-Samosøe P. An investigation into the floating behaviour of a pectin-Containing anti-reflux Formulation (FF5005) by means of gamma scintigraphy. Scand. J. Gastroenterol. 1988; 23: 920–924
   PubMed Web of Science ®Google Scholar
• Washington N., Wilson C. G., Williams D. L., Robertson C. An investigation into the effect of cimetidine pre-treatment on raft formation of an anti-reflux agent. Aliment. Pharmacol. Ther. 1993; 7: 553–559
   PubMed Web of Science ®Google Scholar
• Waterhouse E. T., Washington C., Washington N. An investigation into the efficacy of the pectin based anti-reflux formulation-Aflurax. Int. J. Pharm. 2000; 209: 79–85
   PubMedGoogle Scholar
• http://class.fst.ohio-state.edu/FST605/lectures/lect20.html Web ref
   Google Scholar
• http://www.cybercolloids.net/library/carob/structure.php Web ref
   Google Scholar
• http://www.cybercolloids.net/library/carrageenan/structure.php Web ref
   Google Scholar
• http://www.cybercolloids.net/library/pectin/structure.php Web ref
   Google Scholar
• http://www.cybercolloids.net/library/xanthan/structure.php Web ref
   Google Scholar
• http://www.foodproductdesign.com/archive/1999/1299ap.html Web ref
   Google Scholar
• http://www.lsbu.ac.uk/water/hyalg.html Web ref
   Google Scholar